Ironwood Paying $1bn For VectivBio To Extend Its GI Franchise Beyond Linzess
Phase III Data For Apraglutide Due In Late 2023
Executive Summary
Ironwood said it believes VectivBio’s once-weekly GLP-2 analog apraglutide is differentiated from Takeda’s once-daily Gattex in short bowel syndrome and could generate $1bn in peak sales.
You may also be interested in...
Ironwood Hits Phase III Endpoint In SBS-IF, But Shareholders Show Wariness
Looking to compete with Takeda’s Gattex in short bowel syndrome with intestinal failure, Ironwood succeeds in a Phase III trial, but investors may be concerned with misses on secondary endpoints.
Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’
Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.
Ironwood Gears Up To Compete In Competitive Gastrointestinal Markets
With the acquisition of Swiss biotech firm VectivBio in late June, Ironwood Pharmaceuticals has firmly positioned itself as a gastrointestinal-focused company.